Xcout Intel
Curis, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Curis, Inc. among biotechnology companies — ranked by similarity to what Curis, Inc. actually does, not by market-cap band.
Subscribe to see Curis, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Curis, Inc.
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
Curis, Inc. at a glance
Curis, Inc. is a biotechnology company headquartered in Lexington, United States. It is publicly listed (CRIS) with a market capitalisation of $3.5M. Xcout tracks 15 named people at Curis, Inc., including James E Dentzer (President, Chief Executive Officer, Secretary, Treasurer & Director).
Curis, Inc. leadership
- James E DentzerPresident, Chief Executive Officer, Secretary, Treasurer & Director
- James DentzerChief Executive Officer and a member of the Board of Directors
- Diantha DuvallChief Financial Officer and Principal Financial & Accounting Officer
- Jonathan ZungChief Development Officer
- Ahmed HamdyChief Medical Officer
- Mark W. NoelVice President of Technology Management & Intellectual Property
9 more named people on record for Curis, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Curis, Inc. competitors
Ranked by semantic similarity — how close each company is to Curis, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Agenus Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on the discovery and development of better immunotherapies and cancer treatments.
Similar biotechnology company
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Similar biotechnology company
CureLab Oncology Inc. is a clinical-stage biotechnology company headquartered in the greater Boston area that develops new anti-cancer biologics, with its lead product being the immuno-oncology agent Elenagen.
Similar biotechnology company
Curelab Veterinary Inc. is a biotechnology company headquartered in Boston, Massachusetts, devoted to developing innovative veterinary therapeutics and treatments to help pets combat cancer and live longer lives.
Similar biotechnology company
Triana Biomedicines, Inc. is a private biotechnology company focused on targeted molecular glue discovery. The company is headquartered in Lexington, Massachusetts.
Similar biotechnology company
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Similar biotechnology company
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Similar biotechnology company
PIC Therapeutics, Inc. is a biopharmaceutical company headquartered in Natick, Massachusetts, dedicated to developing life-changing medicines for patients with cancer. The company focuses on oncology research and therapeutic product development.
Biotech
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
Biotech
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Similar biotechnology company
Angiex Inc. is a private biotechnology company that focuses on novel biology to address the hallmarks of cancer lethality. The firm develops safe and effective cancer therapies and is located in Cambridge, Massachusetts.
Similar biotechnology company
Cypre Inc. is a biotechnology company headquartered in San Francisco, California, that develops 3D tumor models and oncology platforms for drug discovery.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Curis, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Curis, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →